Request Demo

Last update 07 Sep 2026

Lutikizumab

Last update 07 Sep 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Bispecific antibody

Synonyms

Immunoglobulin, anti-(interleukin 1.beta./interleukin 1.alpha.) (synthetic human a-1234138 heavy chain), disulfide with synthetic human a-1234138 light chain, dimer, lutikizumab, A-1234138

+ [1]

Target

IL-1α x IL-1β

Action

inhibitors

Mechanism

IL-1α inhibitors(Interleukin-1 alpha inhibitors), IL-1β inhibitors(Interleukin-1 beta inhibitors)

Therapeutic Areas

Infectious DiseasesSkin and Musculoskeletal DiseasesOther Diseases+ [3]

Active Indication

Hidradenitis SuppurativaRheumatoid ArthritisArthritis, Psoriatic+ [4]

Inactive Indication

Colitis, UlcerativeOsteoarthritis, Knee

Originator Organization

AbbVie, Inc.

Active Organization

AbbVie, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 3

First Approval Date-

RegulationOrphan Drug (Japan)

Structure/Sequence

Sequence Code 9550995H

Source: *****

Sequence Code 9551004L

Source: *****

Clinical Trials associated with Lutikizumab

NCT06972446

/ RecruitingPhase 2

A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderately to Severely Active Rheumatoid Arthritis

Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies for the treatment of moderately to severely active Rheumatoid Arthritis (RA).
This study currently includes 3 substudies evaluating different treatments in participants with RA. Substudy 1 will evaluate lutikizumab monotherapy (treatment given alone) compared to placebo (looks like the study treatment but contains no medicine). Substudy 2 will evaluate ravagalimab monotherapy compared to placebo and Substudy 3 will evaluate lutikizumab and ravagalimab combination therapy (treatments given together) compared to placebo. Approximately 180 participants who have failed 1 or 2 biologic/targeted synthetic disease-modifying antirheumatic drug (tsDMARD) therapies will be enrolled in the study at approximately 65 sites worldwide.
There may be higher treatment burden for participants in this trial compared to their standard of care treatment without participating in this study. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Start Date20 Jun 2025

Sponsor / Collaborator

AbbVie, Inc.

NCT06865105

/ RecruitingPhase 2

A Phase 2 Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Active Psoriatic Arthritis

Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms.
The therapies being assessed in this sub-study are risankizumab and lutikizumab. Participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: lutikizumab monotherapy, risankizumab monotherapy or a combination therapy of lutikizumab and risankizumab. Around 120 participants will be enrolled in the study at approximately 40 sites worldwide.
There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Start Date11 Apr 2025

Sponsor / Collaborator

AbbVie, Inc.

NCT06718101

/ Active, not recruitingPhase 2

A Phase 2 Multicenter Platform Trial of Targeted Immunomodulator Therapies for Moderate to Severe Atopic Dermatitis

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. The purpose of this study is to evaluate the clinical efficacy and safety of single therapies and/or combination therapies for moderate to severe AD through multiple substudies.
This study will consist of multiple substudies. Substudy 1 will have a randomized, open-label period 1 followed by a lutikizumab treatment period 2 enrolling 80 participants at a 1 to 1 ratio.
In Substudy 1, participants will receive subcutaneous (SC) injections of lutikizumab or matching placebo every other week for 16 weeks followed by an additional 32 weeks of SC injections of lutikizumab every other week for a total of 52 weeks.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and biomarker collections.

Start Date19 Dec 2024

Sponsor / Collaborator

AbbVie, Inc.

100 Clinical Results associated with Lutikizumab

100 Translational Medicine associated with Lutikizumab

100 Patents (Medical) associated with Lutikizumab

Literatures (Medical) associated with Lutikizumab

01 May 2026·JAMA Dermatology

Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure

Article

Author: Giamarellos-Bourboulis, Evangelos J. ; Kimball, Alexa B. ; Zhan, Tianyu ; Ackerman, Lindsay ; Lima, Hermenio ; Akbari, Mona ; Williams, David A. ; Drogaris, Leonidas ; Bechara, Falk G. ; Gu, Yihua ; Lee, Christine M. ; Sawicki, Konrad T.

Importance:

Hidradenitis suppurativa (HS) is a debilitating inflammatory skin disease with limited therapeutic options.

Objective:

To assess the efficacy and safety of lutikizumab, a dual-variable domain interleukin 1α/1β antagonist, for adult participants with moderate to severe HS who experienced anti–tumor necrosis factor (TNF) therapy failure.

Design, Setting, and Participants:

This phase 2, double-blind, placebo-controlled randomized clinical trial was conducted at 45 sites in 8 countries or territories (Australia, Canada, Germany, Greece, Japan, Puerto Rico, Spain, and the US) between December 28, 2021, and November 27, 2023, and included a 35-day screening period, a 16-week treatment period, and a 9-week safety follow-up. Data were analyzed in December 2023. Participants 18 years or older with a diagnosis of HS for 12 months or longer who experienced anti-TNF treatment failure were enrolled.

Interventions:

Eligible participants were randomized 1:1:1:1 to receive lutikizumab, 300 mg, every week; lutikizumab, 300 mg, every other week; lutikizumab, 100 mg, every other week; or placebo, every week. The trial drug was administered starting at baseline and through week 16.

Main Outcomes and Measures:

The primary end point was achieving a Hidradenitis Suppurativa Clinical Response (HiSCR 50) at week 16. The secondary efficacy objective was achieving at least a 30% reduction and at least 1-unit reduction from baseline in Patient's Global Assessment of skin pain (Numerical Rating Scale [NRS] 30) after 16 weeks of treatment among among patients with a baseline NRS 3 or greater. Additional end points included achieving HiSCR 75 and HiSCR 90, change and percentage change from baseline in draining tunnels, and change from baseline in Dermatology Life Quality Index total scores.

Results:

A total of 153 participants received at least 1 dose of the trial medication (94 female individuals [61.4%]; mean [range] age, 40.5 [19-75] years; 108 patients [70.6%] at Hurley stage III). At week 16, 19 (48.7%), 22 (59.5%), and 10 participants (27.0%) receiving lutikizumab, 300 mg, every week; lutikizumab, 300 mg, every other week; and lutikizumab, 100 mg, every other week, respectively, achieved HiSCR50 at week 16 compared with placebo (35.0%); posterior probabilities of positive treatment effect vs placebo were 89.3%, 98.5%, and 22.8%, respectively, using a bayesian analysis. Among participants with baseline NRS scores of 3 or greater, 10 (34.5%) who received lutikizumab, 300 mg, every other week and 8 (34.8%) who received lutikizumab, 300 mg, every week achieved an NRS30 response compared with 4 (12.9%) who received placebo. There were no deaths or treatment-emergent adverse events of neutropenia, serious hypersensitivity reactions, major adverse cardiovascular events, or opportunistic infections reported.

Conclusions and Relevance:

In this phase 2 randomized clinical trial, lutikizumab, 300 mg, every week and 300 mg every other week showed positive treatment effects vs placebo in a hard-to-treat moderate to severe HS population that experienced anti-TNF therapy failure.

Trial Registration:

ClinicalTrials.gov Identifier: NCT05139602

02 Jan 2026·POSTGRADUATE MEDICINE

Evaluating the promotion of biomechanical changes in osteoarthritis treated with lutikizumab: a systematic review and meta-analysis

Review

Author: Chen, Bo ; Yang, Shili ; Sun, Yu ; Kou, Haiyang ; Liu, Huaiquan ; Zhang, Xinyan ; Lai, Lingyan ; Xu, Yunling

OBJECTIVE:

To evaluate the effect of lutikizumab intervention on patients with osteoarthritis (OA) and provide an evidence-based reference for the clinical application of lutikizumab intervention in patients with osteoarthritis.

METHODS:

Literature databases such as PubMed, Embase, web of science, and the Cochrane Library were searched to collect relevant data on randomized controlled trials (RCTs), clinical trials, and single/double arm non-randomized controlled trials studies of therapy interventions for patients with OA, and meta-analysis was performed using RevMan 5.4.

RESULTS:

A total of 6 randomized controlled studies were included, including 737 patients with osteoarthritis. Meta-analysis showed that compared with the control group, lutikizumab intervention had more gains, IL-α (0.3 mg/kg, Q2W, week2) (MD = -0.67, 95% CI [-1.25,-0.09]; Z = 2.26; p = 0.02), IL-1β (3 mg/kg,Q2W,week2) (MD = -0.58, 95% CI [-1.14, -0.02]; Z = 2.03; p = 0.04) and hsCRP (200 mg,Q2W,week8) (MD = -1.79, 95% CI [-2.09, -1.50]; Z = 11.80; p < 0.00001).

CONCLUSION:

Reducing the OA process with lutikizumab provides a theoretical basis for further investigation of the function of lutikizumab in patients with OA.IL-1 is not only an inflammatory mediator in osteoarthritis, but also a key molecule connecting biomechanical abnormalities and tissue damage.IL-1 inhibitors precisely regulate the spatiotemporal expression of IL-1, and individualize the biomechanical intervention regimens or combination of multiple interventions to achieve optimal therapeutic effects.

01 Sep 2025·JAMA Dermatology

Efficacy and Safety of Medical Interventions for Moderate to Severe Hidradenitis Suppurativa

Review

Author: Midgette, Bria ; Cohn, Erica ; Frasier, Kelly ; Garg, Amit ; Strunk, Andrew

Importance:

There is limited comparative information on regulatory approved and pipeline treatments in hidradenitis suppurativa (HS).

Objective:

To compare efficacy, safety, and tolerability of treatments for moderate to severe HS.

Data Sources:

MEDLINE, Embase, ClinicalTrials.gov, and Cochrane Central Register of Controlled Trials were searched from inception to June 28, 2024.

Study Selection:

Phase 2 and 3 randomized clinical trials of medical interventions (cytokine inhibitors, small molecule inhibitors, cell inhibitors, and other novel immune or inflammatory modifiers) for adults with moderate to severe HS having primary efficacy assessments between 12 and 16 weeks.

Data Extraction and Synthesis:

Data extraction and risk of bias assessments were performed independently by 2 reviewers. Efficacy outcomes were analyzed using random-effects network meta-analysis. Safety and tolerability outcomes were analyzed using pairwise fixed-effect meta-analyses vs placebo. Data analysis was performed between August 22, 2024, and April 7, 2025.

Main Outcomes and Measures:

Primary efficacy, safety, and tolerability outcomes were Hidradenitis Suppurativa Clinical Response (HiSCR)-50, occurrence of serious adverse events (SAEs), and treatment discontinuation due to adverse events, respectively. HiSCR-75 was a secondary efficacy outcome.

Results:

Of 26 eligible trials, 25 had available HiSCR-50 data, including 5767 total patients and 39 unique treatments. Compared with placebo, the following treatments were associated with significantly higher HiSCR-50 response rates: sonelokimab, 120 mg, every 4 weeks; lutikizumab, 300 mg, every 2 weeks; adalimumab, 40 mg, once per week; sonelokimab, 240 mg, every 2 weeks; bimekizumab, 320 mg, every 2 weeks; povorcitinib, 15 mg, once per day; bimekizumab, 320 mg, every 4 weeks; secukinumab, 300 mg, every 4 weeks; and secukinumab, 300 mg, every 2 weeks. Most differences between adalimumab, 40 mg, once per week, and other targeted treatments were not statistically significant. The percentage of patients experiencing SAEs ranged from 0% to 10% in the placebo groups, 0% to 8% in the adalimumab (40 mg, once per week) groups, and 0% to 6% in the other active treatment groups. The percentage of patients discontinuing treatment due to adverse events ranged from 0% to 10% in the placebo groups, 0% to 4% in the adalimumab (40 mg, once per week) groups, and 0% to 15% (ropsacitinib) in the other active treatment groups.

Conclusions and Relevance:

This network meta-analysis provides evidence for the comparative efficacy and safety of currently approved and pipeline medications for moderate to severe HS in the absence of head-to-head trials.

News (Medical) associated with Lutikizumab

06 May 2026

·endpoints.news

Avalo scores much-needed Phase 2 win and $375M raise as it attempts turnaround

Avalo Therapeutics’ comeback bid surged forward Tuesday afternoon, as the immunology biotech secured a mid-stage trial win in an inflammatory skin disorder. Avalo said that both doses of an experimental drug called abdakibart (previously AVTX-009) beat placebo by statistically significant margins in patients with moderate-to-severe hidradenitis suppurativa. With the data, Avalo plans to move the program into Phase 3 and raised $375 million to push that effort through. In response, the biotech’s stock price $AVTX jumped nearly 50% in premarket trading on Wednesday. After the opening bell, its shares were up about 35%. Avalo has seen a number of setbacks over the last few years. Formerly known as Cerecor, the biotech suffered multiple clinical failures nearly a decade ago, when it was focusing on drugs for depression and nicotine withdrawal. The company eventually rebranded to Avalo in 2021, pivoting to immunology and rare disease. Its first efforts in the new areas were also disappointing as it foundered toward microcap status. In 2022, Avalo shuffled its leadership team, conducted layoffs and sold an experimental drug in an effort to stay afloat . Another trial failed in 2023 , that time in asthma, further battering the biotech and sending its market cap to nearly zero. At the end of that year, Avalo had only $7.4 million in cash after spending the year paying down debt. But things started turning around in early 2024, when Avalo bought the AVTX-009 program that became abdakibart. In an acquisition of the private biotech AlmataBio, Avalo secured the drug and a $185 million raise from a number of prominent life sciences investors like OrbiMed. Now, Avalo seems like it might finally have an approvable drug on its hands, some analysts say. In a note to investors Tuesday evening, Stifel analyst Alex Thompson wrote that the drug’s placebo-adjusted effect is “in line” with UCB’s Bimzelx, which pulled in $2.6 billion in sales last year. With a different mechanism of action than Bimzelx — abdakibart is an anti-IL-1β antibody — Thompson said there could be space for both drugs on the market. But abdakibart first has to succeed in Phase 3, and results will be closely compared to an experimental drug from AbbVie called lutikizumab, which is expected to have Phase 3 HS data later this year.

06 May 2026

·www.fiercebiotech.com

Avalo’s phase 2 skin disease win fuels pursuit of AbbVie despite placebo headwind

Avalo filed to raise $375 million to secure enough money to deliver topline phase 3 data. \n A phase 2 trial of Avalo Therapeutics’ hidradenitis suppurativa (HS) candidate hit its primary endpoint, emboldening the biotech to advance toward a registrational study. While the placebo-adjusted result fell short of the bar set by Avalo, analysts and AbbVie’s rival program, the biotech’s stock jumped in premarket trading. Investigators randomized 253 adults with moderate-to-severe HS, an inflammatory skin disease, to take one of two doses of the anti-IL-1β antibody abdakibart or placebo. Like AbbVie’s 1α/1β antagonist lutikizumab, which is in phase 3, the former Eli Lilly asset abdakibart is designed to improve outcomes by neutralizing the activity of a pro-inflammatory cytokine implicated in the disease.Patients in the abdakibart cohorts received either a 600 mg loading dose followed by 300 mg every four weeks, or a 300 mg loading dose followed by 150 mg every two weeks. The primary endpoint looked at HiSCR75, a measure based on a 75% reduction in total abscess and inflammatory nodule count.At Week 16, the HiSCR75 response rate was 42.2% for the 150 mg dose and 42.9% for the 300 mg dose. The placebo-adjusted response rate was 16.9% for the average of the two abdakibart doses, compared to 21% in the weekly dosing cohort of AbbVie’s phase 2 trial. Cross-trial comparisons can be unreliable, but Avalo’s placebo-adjusted HiSCR75 response rate also fell short of other yardsticks. At a TD Cowen event in March, Avalo CEO Garry Neil, M.D., said the biotech expected that “anything over 20% placebo subtracted would be a clear win for the drug, even though we are hoping, and I think we have a reasonable expectation of doing, better than that.” Neil said a 25% placebo-adjusted result would be “a home run” and discussed a “grand slam” scenario in which abdakibart delivered even stronger data.Guggenheim Securities analysts outlined similar expectations in a note to investors in April. The analysts said a 20% placebo-adjusted response rate would be “a competitive outcome,” although they added that a result over 18% “should be well-received by the Street” given the novel biology. Yet Avalo’s share price rose 40% to $22.80 in premarket trading Wednesday following news of its 16.9% placebo-adjusted response rate.Avalo’s inability to hit its 20% target reflected a higher-than-expected placebo response rate. Abdakibart achieved a higher HiSCR75 rate than lutikizumab, with AbbVie reporting responses in 38.5% of patients who received the weekly regimen the Big Pharma took into its pivotal trial. However, Avalo’s placebo response rate, 25.6%, was higher than AbbVie’s 17.5%.Placebo response rates typically fall in the 13% to 18% range, Neil said in March. However, the Avalo CEO highlighted “a couple of highly visible and notable exceptions lately, especially Vela-2,” referring to the MoonLake Immunotherapeutics’ HS trial that missed its primary endpoint last year. MoonLake reported a 25.6% HiSCR75 response rate in Vela-2. The size of Avalo’s trial helped the biotech deliver a statistically significant result despite the placebo response rate. Avalo assumed a 20% placebo response rate when it designed the trial, Neil said at a TD Cowen event in November. Increasing enrollment from 180 to 222 gave Avalo the power to withstand a 22% placebo rate, Neil said, and surpassing that target offered protection against “a placebo surprise.” Avalo plans to move into phase 3 on the strength of the data. The biotech filed to raise $375 million in a stock offering to secure enough money to deliver topline phase 3 data on the drug candidate in HS.

Clinical ResultPhase 2Phase 3Clinical Trial Failure

01 May 2026

·allsci.com

AbbVie Q1’26 Earnings Call: Skyrizi combo doubles remission rates in refractory Crohn’s

During AbbVie’s Q1 2026 earnings conference call, held April 29, 2026, executives discussed the decision to accelerate Phase III development of the Skyrizi (risankizumab) plus ABBV-382 combination in inflammatory bowel disease after interim data showed double the endoscopic remission rate of either monotherapy in a highly refractory Crohn’s disease population. The company has also pulled forward its obesity Phase II program and signaled an earlier-than-expected regulatory submission for etentamig in multiple myeloma. Key Strategic Signals Skyrizi + ABBV-382 Combination: Interim data from AbbVie’s Crohn’s disease platform study showed the combination of Skyrizi (risankizumab) and ABBV-382, an anti-alpha 4 beta 7 antibody, achieved approximately 42% endoscopic remission at week 24 in a population where 82% had failed prior advanced therapies — double the rate observed with either monotherapy. Chief Scientific Officer Roopal Thakkar said the company observed a non-flat exposure-response relationship for ABBV-382, meaning patients with higher drug exposures fared better, and that a Phase IIb study initiating this summer will test a higher dose of ABBV-382 in combination with Skyrizi. AbbVie said it is simultaneously evaluating Phase III acceleration options and will evaluate Skyrizi in combination with ABBV-382 and separately with its extended half-life TL1A antibody, with ulcerative colitis (UC) included alongside Crohn’s disease. The Skyrizi plus lutikizumab cohort within the same platform study was discontinued after failing to differentiate meaningfully from Skyrizi monotherapy. Etentamig regulatory timeline advanced: AbbVie said it now expects to submit etentamig, its B-cell maturation antigen (BCMA) bispecific antibody, for regulatory review by the end of 2026 — earlier than previously guided. The Phase III monotherapy trial in third-line-plus multiple myeloma is tracking ahead of schedule, with a response rate readout anticipated in the third quarter of 2026 and the potential for a concurrent interim progression-free survival (PFS) analysis. If that interim PFS analysis is positive, AbbVie said regulatory submissions would follow in the same year. Thakkar also said plans are underway for a Phase III study evaluating etentamig in combination with pomalidomide in second-line-plus patients, including those previously exposed or refractory to anti-CD38 antibodies or who have lost response to a BCMA-directed CAR-T or antibody-drug conjugate (ADC). ABBV-295 obesity program accelerated: ABBV-295, a long-acting amylin analog with a half-life of approximately 270 hours, produced approximately 10% weight loss after 12 weeks in a multiple ascending dose study conducted predominantly in male, non-obese participants with a mean body mass index of approximately 29. AbbVie said the Phase II program has been pulled forward to the third quarter of 2026, with interim Phase I data in obese patients expected later this year. Thakkar noted the molecule signals through both amylin and calcitonin receptors, and said the pharmacodynamic profile supports potential monthly dosing in the maintenance setting, drawing an analogy to Skyrizi’s durable efficacy beyond its 28-day half-life. AbbVie also flagged active interest in external business development to complement ABBV-295 with additional obesity mechanisms, including oral agents and assets that preserve lean muscle mass. Analyst Pressure Points IBD combination positioning and competitive durability: JPMorgan analyst Christopher Schott pressed management on where the Skyrizi plus ABBV-382 combination fits in the treatment sequence — specifically whether it would be a second-line option post-Skyrizi or could reach the frontline. Thakkar said AbbVie does not intend to restrict the combination to refractory patients, noting that the platform study already enrolled patients who had previously received Skyrizi, vedolizumab, and Rinvoq (upadacitinib), and that frontline IBD use is commercially and clinically relevant given the risk of irreversible gut damage with uncontrolled inflammation. Schott also asked more broadly about AbbVie’s ability to sustain its immunology competitive position given increasing pipeline activity across the sector. Chief Executive Officer Robert Michael pointed to recent business development transactions — including Capstan Therapeutics for in vivo CAR-T B-cell depletion, Nimble Therapeutics for oral peptides, and additions of TL1A and IRAK4 mechanisms — as evidence that AbbVie is building depth beyond Skyrizi and Rinvoq for the next decade. RemeGen PD-1/VEGF bispecific differentiation: Deutsche Bank analyst James Shin pressed Thakkar on how RC-148, the PD-1/VEGF bispecific antibody acquired through the RemeGen agreement, can differentiate given its later entry into a field already occupied by established competitors. Thakkar said AbbVie’s strategy is not to develop RC-148 as a standalone asset but to deploy it as a combination partner for Temab-A, the company’s c-MET ADC, across colorectal, lung, and ovarian cancers — framing the asset’s value as contingent on ADC combinations rather than monotherapy positioning. Forward-Looking Catalysts Q3 2026 — etentamig Phase III response rate readout: The Phase III trial evaluating etentamig monotherapy in third-line-plus multiple myeloma is expected to deliver a response rate readout in the third quarter of 2026, with a potential concurrent interim PFS analysis. AbbVie said a positive interim PFS result would trigger regulatory submissions by year-end, making this the most time-sensitive oncology catalyst on the company’s near-term calendar. The trial’s ahead-of-schedule pace reduces execution risk on that timeline. H2 2027 readout for Temab-A colorectal cancer Phase III: Following AbbVie’s decision to pivot the next-generation c-Met directed ADC telisotuzumab adizutecan (Temab-A) colorectal cancer pivotal strategy from c-MET-selected monotherapy to an all-comers combination with bevacizumab, the company said it expects an initial data readout from the Phase III trial in the second half of 2027. The strategic rationale cited was a 30% objective response rate and 97% confirmed disease control rate for Temab-A plus bevacizumab versus 0% and 70%, respectively, for Lonsurf (trifluridine/tipiracil) plus bevacizumab as the comparator, with responses observed regardless of c-MET expression level. AbbVie also said Temab-A received its first breakthrough therapy designation as a monotherapy in second-line-plus EGFR wild-type non-squamous non-small cell lung cancer (NSCLC), with a Phase III trial in that setting in planning. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Phase 2Phase 3Clinical ResultBreakthrough TherapyPhase 1

100 Deals associated with Lutikizumab

External Link

KEGG	Wiki	ATC	Drug Bank
D12370	-	-	DB16224

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hidradenitis Suppurativa	Phase 3	United States	AbbVie, Inc.	27 Jun 2024
Hidradenitis Suppurativa	Phase 3	Japan	AbbVie, Inc.	27 Jun 2024
Hidradenitis Suppurativa	Phase 3	Argentina	AbbVie, Inc.	27 Jun 2024
Hidradenitis Suppurativa	Phase 3	Australia	AbbVie, Inc.	27 Jun 2024
Hidradenitis Suppurativa	Phase 3	Austria	AbbVie, Inc.	27 Jun 2024
Hidradenitis Suppurativa	Phase 3	Belgium	AbbVie, Inc.	27 Jun 2024
Hidradenitis Suppurativa	Phase 3	Bosnia and Herzegovina	AbbVie, Inc.	27 Jun 2024
Hidradenitis Suppurativa	Phase 3	Bulgaria	AbbVie, Inc.	27 Jun 2024
Hidradenitis Suppurativa	Phase 3	Canada	AbbVie, Inc.	27 Jun 2024
Hidradenitis Suppurativa	Phase 3	Chile	AbbVie, Inc.	27 Jun 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AAD2026	Phase 2	Hidradenitis Suppurativa	47	Lutikizumab 300 mg	dvkjfdkzty(hoxmilacfv) = lfmchmozqy mzmoejvtxg (wdueewiedg ) View more	Positive	27 Mar 2026
AAD2025	Phase 2	Hidradenitis Suppurativa	153	Lutikizumab 300mg EW	bdffxmfuzv(evnpwstkmv) = mcdbizxage wxzqrnyjlm (wygjseihny ) View more	Positive	07 Mar 2025
				Lutikizumab 300mg EOW	bdffxmfuzv(evnpwstkmv) = ewtfgmlvzk wxzqrnyjlm (wygjseihny ) View more
NCT05139602 (Biospace) Manual	Phase 2	Hidradenitis Suppurativa	153	lutikizumab	tmazdiiwzm(vojoodqeen) = doibcxoocz jbqdbognee (pwwcfaynpd ) View more	Positive	08 Jan 2024
				placebo	rwtabufzgh(orvyhschpj) = nkeqxyhpyr gwotdxoppw (ztwlgmabwi ) View more
NCT02087904 (CTgov)	Phase 2	Osteoarthritis, Knee	350	Placebo	gymoxwvaaw(vpfnkieylm) = pipnmafrgc kwuyezevgg (zivxnxzcxg, nawabluhfp - ldfgxrcqrf) View more	-	28 Aug 2019
NCT01668511 (Pubmed \| Osteoarthritis Cartilage)	Phase 1	Osteoarthritis, Knee	36	ABT-981 0.3 mg/kg	jchfsbajbr(bozvekwnav) = aaqnxjyujo icbnvzykwe (apazqgkqsv ) View more	-	01 Dec 2017
				ABT-981 1 mg/kg	jchfsbajbr(bozvekwnav) = tjpctblojh icbnvzykwe (apazqgkqsv ) View more
NCT02384538 (CTgov)	Phase 2	Osteoarthritis	132	Placebo for ABT-981 (Placebo)	cvzzxkwmjx(adxkruahsr) = gjrsyguhlc zstjpaqkxj (gtujqqiteu, hzdscuzbwi - zdodtxehmc) View more	-	13 Jul 2017
				ABT-981 (ABT-981)	cvzzxkwmjx(adxkruahsr) = hcgiqgnwzw zstjpaqkxj (gtujqqiteu, ftxsfanhih - vsyktqljpv) View more
EULAR2014	Phase 1	Osteoarthritis	-	ABT-981	lxdyooskbu(pdxrewwlnm) = Measurable ADA titers were detected in 7 subjects on active treatment gtegyocrta (redgmvcqwz ) View more	-	11 Jun 2014

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis